Sucharita Mistry, PhD

Overall survival data were not mature.

Convalescent plasma therapy provided a survival benefit in the overall cohort and in higher-risk subgroups.

The mutation rate was significantly higher in metastatic breast cancer than in nonmetastatic breast cancer.

At 4 years, there was no significant difference in overall survival.

Capecitabine should remain the standard adjuvant treatment, according to researchers.

Data showed increases in endometrial cancer and obesity in women younger than 40.

Younger patients had a significant decrease in sleep time on days they received dexamethasone.

There was no improvement in overall survival.

Statistically significant benefit was observed with extended letrozole therapy in patients with HR+ breast cancer identified as low-risk, but not in high-risk patients.

The 70-gene signature can identify patients with an ultralow risk of distant recurrence, which can be used to de-escalate treatment and reduce side effects.